



African Swine Fever Virus Prevention and Control

Guest Editor:

Dr. Christopher Netherton

african Swine Fever Vaccinology
Group, The Pirbright Institute,
Surrey GU24 0NF, UK

Deadline for manuscript
submissions:

closed (31 January 2021)

Message from the Guest Editor

Dear Colleagues,

Since its introduction into Georgia in 2007, African swine fever virus has spread across both Europe and Asia and has been responsible for the deaths of hundreds of millions of animals. Virulent strains of the virus cause a haemorrhagic fever to occur in domestic pigs and wild boar that is invariably fatal. The main tools missing from the African swine fever control kit are vaccines suitable for preventing disease in both domestic and wild animals. Without such vaccines, it is difficult to envisage how the current epidemic can be brought under control and the disease eradicated. Novel approaches are required, as, to date, inactivated viruses and attenuation through tissue culture passage have not yielded safe and effective vaccines. Due to the severity of the current African swine fever virus epidemic, alternative strategies including prophylaxis may also need to be considered. Deployment of such novel control strategies will require the development of effective implementation strategies based on robust epidemiological modeling.

Dr. Christopher Netherton
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com